Trade Info : Alembic gets US tentative approval for a cancer drug called Larotrectinib

Symbol

APLLTD

Company

Alembic Pharmaceuticals Ltd

Category

New Product Approval

Source

Press Release

91 million USD

241

221

News Summary

Alembic Pharmaceuticals received tentative approval from the US FDA for its Larotrectinib capsules.
This generic version is for treating specific solid tumors in adults and children.
The company filed for this approval as the first applicant for this specific drug.

Why This Matters

This approval means Alembic can potentially sell this drug in the US market.
The estimated market size for this drug is around 91 million dollars for the next year.
Investors should know this is a significant new revenue opportunity for the company.

Fundamental Backdrop (FY – FY 2026)

Metric	Value
Estimated Market Size	91 million US dollars
Total USFDA Approvals	241
Final USFDA Approvals	221
Tentative USFDA Approvals	20

Analyst's View

This suggests the company is successfully expanding its international business.
The company appears to be a leader in creating generic versions of major drugs.
Investors may want to watch how quickly they get final approval to start sales.

Buy

Confidence 85%

Conviction Level 85%

The company has secured a major new product in a growing global market.

Key Positives

Alembic is the first company to apply for this specific generic drug version.
The drug targets a serious medical condition with currently limited treatment options.
The company has a strong track record of getting US regulatory approvals.

Key Risks

Tentative approval is not final, and the US FDA could still reject the drug later.
The estimated market size is based on current data and might change.
Competition from other generic drug makers could grow over time.

HorizonMedium term

Confidence LevelHigh

Suggested position size: Moderate allocation

⚠️

Disclaimer This analysis is for informational purposes only and does not constitute financial advice. Do your own research and consult a qualified financial professional before making any investment decisions.